|
|
|
|
|
|
|
Product Name |
(+)-Negamycin |
|
|
| |
|
|
| Product Specifications | |
|
| catalogue no. | ME051 | |
| chemical name | (+)-Negamycin | |
| IUPAC name | (2-((3R,5R)-3,6-diamino-5-hydroxyhexanoyl)-1-methylhydrazinyl)- acetic acid | |
| molecular formula | C9H20N4O4 | |
| molecular weight [g/mol] | 248.28 |
|
| CAS | 33404-78-3 | |
| purity | 95%+ | |
| category | Medchem Compounds | |
| melting point | n.d. | |
| boiling point | n.d. | |
| appearance | solid | |
| solubility | water | |
| long term storage | -20oC | |
| Spectra | 1-H NMR | |
| NMR analytics | 600 MHz (CDCl3) | |
|
| Safety Information | |
|
| R-sentence | R: 36/37/38 | |
| S-sentence | S: 26-24/25 | |
| hazardous substance symbol | Xn | |
| safety info | Caution, substance not fully tested. Potential health effects. | |
|
| References |
Hamada et al.: Hydrazide antibiotic isolated from strains related to Streptomyces purpeofuscus. J. Antibiot. 23, 170 (1970)
Ed T. Buurman et al.: Illicit Transport via Dipeptide Transporter Dpp is Irrelevant to the Efficacy of Negamycin in Mouse Thigh Models of Escherichia coli Infection. ACS Infect. Dis. 2015, 1, 222-230
A. Taguchi, K. Hamada, Y. Hayashi: Chemotherapeutics overcoming nonsense mutation-associated genetic diseases: medicinal chemistry of negamycin. J. Antibiot (Tokyo) 71, 205-214 (2018)
Y. Hayashi et al.: Negamycin Analogue with Readthrough-Promoting Activity as a Potential Drug Candidate for Duchenne Muscular Dystrophy. ACS Med. Chem. Lett. 2012, 3, 118-122
Thomas A. Steitz et al.: Negamycin inferes with decoding and translocation by simultaneous interaction with rRNA and tRNA. Molecular Cell 56, 1-10, 2014-11-20
Y. Hayashi et al.: Structure-activity relationship study of Leucyl-3-epi-deoxynegamycin for potent premature termination codon readthrough. ACS Med. Chem. Lett. 2017, 8, 1060-1065 | |
|
| Ordering Information |
|
|
|
Cat. No. |
| |
Product Name |
| |
Quantity |
| |
Price |
|
|
ME051.1 |
|
(+)-Negamycin |
|
1 mg |
|
990,- € |
|
ME051.2 |
|
(+)-Negamycin |
|
2.5 mg |
|
1980,- € |
|
|
|
|